185 related articles for article (PubMed ID: 26294112)
21. Double-hit diffuse large B-cell lymphoma.
Friedberg JW
J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
[No Abstract] [Full Text] [Related]
22. Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma.
Aricò A; Ferraresso S; Bresolin S; Marconato L; Comazzi S; Te Kronnie G; Aresu L
PLoS One; 2014; 9(11):e111817. PubMed ID: 25372838
[TBL] [Abstract][Full Text] [Related]
23. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
24. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
25. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
26. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
28. Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
Rund D
Leuk Lymphoma; 2014 Sep; 55(9):1966-7. PubMed ID: 24588736
[No Abstract] [Full Text] [Related]
29. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
Brauner S; Zhou W; Backlin C; Green TM; Folkersen L; Ivanchenko M; Löfström B; Xu-Monette ZY; Young KH; Møller Pedersen L; Boe Møller M; Sundström C; Enblad G; Baecklund E; Wahren-Herlenius M
J Intern Med; 2015 Sep; 278(3):323-32. PubMed ID: 25880119
[TBL] [Abstract][Full Text] [Related]
30. Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
Chigrinova E; Mian M; Shen Y; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Zucca E; Kwee I; Bertoni F
Br J Haematol; 2011 May; 153(4):499-503. PubMed ID: 21418177
[TBL] [Abstract][Full Text] [Related]
31. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
32. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
33. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
34. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Yamada T; Sawada M; Takahashi T; Yamada T; Seishima M; Moriwaki H; Takami T
Leuk Lymphoma; 2012 Aug; 53(8):1494-500. PubMed ID: 22280534
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
[TBL] [Abstract][Full Text] [Related]
37. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
[No Abstract] [Full Text] [Related]
38. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
40. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Leuk Lymphoma; 2017 Mar; 58(3):736-739. PubMed ID: 27686739
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
